TY  - JOUR
TI  - Castleman Disease: A Multicenter Case Series from Turkey
AB  - Objective: Castleman disease (CD) is a rare disease also known as
angiofollicular lymph node hyperplasia. The two main histological
subtypes are the hyaline vascular and plasma cell variants. It is further
classified as unicentric CD (UCD) or multicentric CD (MCD) according
to the anatomical distribution of the disease and the number of lymph
nodes involved. The aim of this multicenter study was to evaluate all
cases of CD identified to date in Turkey to set up a national registry to
improve the early recognition, treatment, and follow-up of CD.
Materials and Methods: Both adult (n=130) and pediatric (n=10)
patients with lymph node or involved field biopsy results reported as
CD were included in the study. Patients’ demographic information,
clinical and laboratory characteristics, imaging study results, treatment
strategies, and clinical outcomes were evaluated retrospectively.
Results: A total of 140 patients (69 male and 71 female) with a
diagnosis of UCD (n=73) or MCD (n=67) were included. The mean
age was 39 years in the UCD group and 47 years in the MCD group.
Female patients were more common in the UCD group. The most
common histological subtype was hyaline vascular for both UCD
and MCD patients. Asymptomatic patients were more common in
the UCD group. Anemia, elevations of acute phase reactants, and
hypoalbuminemia were more common in the MCD group. The most
commonly used treatment strategies for UCD were surgical excision,
rituximab, and radiotherapy, respectively. All UCD patients were alive
at a median of 19.5 months of follow-up. The most commonly used
treatment strategies for MCD were methyl prednisolone, R-CHOP,
R-CVP, and rituximab. Thirteen MCD patients had died at a median of
34 months of follow-up.
Conclusion: This study is important in presenting the patient
characteristics and treatment strategies for CD from Turkey, with the
potential of increasing awareness about CD. Treatment data may help
in making decisions, particularly in countries that do not have access
to siltuximab. However, larger prospective studies are needed to make
definitive conclusions.
AU  - Kis, Cem
AU  - İpek, Yıldız
AU  - belen, fatma burcu
AU  - KARAKUŞ, Sema
AU  - Guven, Zeynep Tugba
AU  - Gündüz, Eren
AU  - ELVERDİ, TUĞRUL
AU  - Karatas, Ayse
AU  - ÖZÇELİK ŞENGÖZ, CEYDA
AU  - AKDENİZ, Aydan
AU  - karaman gülsaran, sedanur
AU  - ÜMİT, Elif Gülsüm
AU  - Eroğlu küçükdiler, Ayşe hilal
AU  - Toret, Ersin
AU  - Özdemir, Nihal
AU  - Ören, Hale
AU  - Kirkizlar, Hakki Onur
AU  - Bakanay, Sule Mine
AU  - Akgun Cagliyan, Gulsum
AU  - BULDUK, TUBA
AU  - Kartal, Ibrahim
AU  - ÖZCAN, Alper
AU  - MARAL, SENEM
AU  - Ozkocaman, Vildan
AU  - CELKAN, TÜLIN TIRAJE
AU  - Paydas, Semra
AU  - Kucukyurt, Selin
AU  - Özkalemkaş, Fahir
AU  - candar, ömer
AU  - CANBOLAT, Aylin
AU  - Ceneli, Ozcan
AU  - Ekinci, Omer
DO  - 10.4274/tjh.galenos.2022.2021.0670
PY  - 2022
JO  - Turkish Journal of Hematology
VL  - 39
IS  - 2
SN  - 1300-7777
SP  - 130
EP  - 135
DB  - TRDizin
UR  - http://search/yayin/detay/515131
ER  -